DMAE (Dimethylaminoethanol)
Naturally occurring amino alcohol found in fish and produced endogenously in small amounts. Precursor to acetylcholine via choline. Limited clinical evidence for cognitive enhancement despite long history of use. Excreted ~16-69% in urine, ~3-22% as exhaled CO2. Formerly marketed as Deanol for learning disorders.
Projected serum levels — 250 mg, once daily
Maintenance schedule: 250 mg once daily (oral).
Modeled steady state after ~1 days: peak ≈ 131 mg, trough ≈ 1.8 mg body load. Population-based estimate over 15 days for a 250 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Nootropic
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 3.5 h
- Common dose
- 250 mg
- Suggested maximum
- 750 mg/day
- Reference dose range
- 125–750 mg (single dose)
- Suggested cadence
- once daily
Research behind this entry
-
Effects of dimethylaminoethanol pyroglutamate (DMAE p-Glu) against memory deficits induced by scopolamine: evidence from preclinical and clinical studies
Clinical study showed DMAE pyroglutamate significantly improved Buschke memory test scores and choice reaction time in healthy young males with scopolamine-induced cognitive deficits.
-
The effects of deanol on cognitive performance and electrophysiology in elderly humans
Study of deanol (900 mg/day for 21 days) in elderly subjects found no significant effects on word learning, simple reaction time, or complex reaction time.
-
Senile dementia: treatment with deanol
Early clinical study in 14 senile outpatients found 4 weeks of deanol treatment showed some behavioral improvements but no statistically significant changes in cognitive test performance.
3 published studies referenced in the app, each with a plain-language summary.